Thetis Awarded $1.9M NIH Grant to Advance TP-252 into Clinical Trials for Ulcerative Colitis
News
Thetis Pharmaceuticals recently received a $1.9 million fast-track Small Business Innovation Research grant from the National Institutes of Health (NIH) to help advance the development of TP-252, an investigational oral therapy for ulcerative ... Read more